Lord Abbett & CO. LLC Cuts Position in AbbVie Inc. $ABBV

Lord Abbett & CO. LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 9.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,038,603 shares of the company’s stock after selling 111,771 shares during the quarter. Lord Abbett & CO. LLC’s holdings in AbbVie were worth $237,310,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ABBV. Chelsea Counsel Co. purchased a new position in AbbVie in the third quarter valued at approximately $26,000. Litman Gregory Wealth Management LLC purchased a new position in AbbVie in the fourth quarter valued at approximately $28,000. Westend Capital Management LLC purchased a new position in AbbVie in the fourth quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX purchased a new position in AbbVie in the third quarter valued at approximately $31,000. Finally, Legacy Wealth Managment LLC ID raised its holdings in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after buying an additional 73 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 1.2%

Shares of NYSE:ABBV opened at $227.54 on Friday. AbbVie Inc. has a 52-week low of $181.73 and a 52-week high of $244.81. The company has a 50 day moving average of $211.05 and a two-hundred day moving average of $219.07. The company has a market capitalization of $402.02 billion, a price-to-earnings ratio of 112.09, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter last year, the company earned $2.46 earnings per share. AbbVie’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, equities analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ABBV. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a research report on Thursday, April 30th. Barclays began coverage on shares of AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective for the company. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Monday. Finally, William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $253.43.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.